INFI - Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022.
| Conference Call & Webcast Details |
| Date: |
| Tuesday, May 3rd |
| Time: |
| 4:30 pm Eastern Time |
| Webcast: |
| Toll Free: |
| (877) 316-5293 |
| International: |
| (631) 291-4526 |
| ID Number: |
| 6618485 |
A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity’s website at https://www.infi.com/ and will be available on Infinity's website for 30 days following the event.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic in multiple clinical studies. MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022. MARIO-3 is the first eganelisib combination study in frontline advanced cancer patients and is evaluating eganelisib in combination with Tecentriq ® and Abraxane ® in frontline TNBC and in combination with Tecentriq and Avastin ® in frontline RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo ® (nivolumab) in I/O naïve urothelial cancer. MARIO-P is a platform clinical program to evaluate eganelisib across various solid tumor indications, which the Company expects to initiate on a rolling basis in 3Q 2022. For more information on Infinity, please refer to Infinity's website at www.infi.com .
Tecentriq ® is a registered trademark of Genentech, Inc.
Abraxane ® is a registered trademark of Abraxis BioScience, LLC.
Opdivo ® is a registered trademark of Bristol Myers Squibb.
Avastin ® is a registered trademark of Genentech, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005162/en/
Irina Koffler
LifeSci Advisors, LLC
646-970-4681
ikoffler@lifesciadvisors.com